Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Surgery 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Ductal Adenocarcinoma 1 Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1 Multiple Myeloma 1 Medulloblastoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 HER2-positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms 1 Breast Cancer Invasive 1

Interventions

Letrozole 26 Fulvestrant 25 Specimen Handling 20 ribociclib 17 Paclitaxel 16 Capecitabine 16 pembrolizumab 15 palbociclib 15 Trastuzumab 14 Carboplatin 14 exemestane 13 abemaciclib 12 Tamoxifen 12 Anastrozole 12 Magnetic Resonance Spectroscopy 11 pertuzumab 9 trastuzumab deruxtecan 8 Biopsy 8 Goserelin 7 inavolisib 6 giredestrant 6 elacestrant 6 Radiotherapy 6 Cyclophosphamide 6 130-nm albumin-bound paclitaxel 6 patritumab deruxtecan 5 eribulin 5 Taxes 5 Standard of Care 5 Gonadotropin-Releasing Hormone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Neoadjuvant Therapy × 30 days × Clear all

NCT05296746 2026-05-14

RIBOLARIS

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡